Drug General Information
Drug ID
D0V0CJ
Former ID
DNCL002647
Drug Name
CO-101
Drug Type
Small molecular drug
Indication Metastatic pancreatic [ICD10:C25.9] Phase 2 [523237]
Company
Clovis Oncology
Structure
Download
2D MOL

3D MOL

Formula
C11H13NO3
Canonical SMILES
CN(C)C(=O)C1=CC=CC=C1C(=O)OC
InChI
1S/C11H13NO3/c1-12(2)10(13)8-6-4-5-7-9(8)11(14)15-3/h4-7H,1-3H3
InChIKey
HJPZFXYWMRWNHV-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Human DNA Target Info Inhibitor [528281]
Ribonucleoside-diphosphatereductase subunit M2 Target Info Inhibitor [528281]
BioCyc Pathway Pyrimidine deoxyribonucleotides biosynthesis from CTP
Pyrimidine deoxyribonucleotides de novo biosynthesis
Guanosine nucleotides de novo biosynthesis
Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis
Superpathway of purine nucleotide salvage
Purine nucleotides de novo biosynthesis
Adenosine deoxyribonucleotides de novo biosynthesis
Guanosine deoxyribonucleotides de novo biosynthesis
KEGG Pathway Purine metabolism
Pyrimidine metabolism
Glutathione metabolism
Metabolic pathways
p53 signaling pathway
NetPath Pathway EGFR1 Signaling Pathway
PANTHER Pathway p53 pathway
De novo purine biosynthesis
De novo pyrimidine deoxyribonucleotide biosynthesis
Pathway Interaction Database E2F transcription factor network
PathWhiz Pathway Purine Metabolism
Pyrimidine Metabolism
Reactome E2F mediated regulation of DNA replication
G1/S-Specific Transcription
WikiPathways Nucleotide Metabolism
Retinoblastoma (RB) in Cancer
Metabolism of nucleotides
Fluoropyrimidine Activity
References
Ref 523237ClinicalTrials.gov (NCT01233375) Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma. U.S. National Institutes of Health.
Ref 528281Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.